Company news

BioCryst Pharmaceuticals, Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

BioCryst to Report Fourth Quarter 2021 Financial Results on February 23

February 8, 2022

BioCryst Appoints Machelle Sanders to Board of Directors

February 7, 2022

BioCryst to Present New ORLADEYO® (berotralstat) Data at 2022 American Academy of Allergy, Asthma & Immunology Annual Meeting

January 31, 2022

BioCryst Announces Preliminary Full Year 2021 ORLADEYO® (berotralstat) Net Revenue and Provides Full Year 2022 ORLADEYO Net Revenue and Peak Sales Guidance

January 9, 2022

BioCryst Begins Patient Enrollment in REDEEM-1 Pivotal Trial Evaluating BCX9930 as Oral Monotherapy for Patients with PNH

January 6, 2022

BioCryst Begins Patient Enrollment in REDEEM-2 Pivotal Trial Evaluating BCX9930 as Oral Monotherapy for Patients with PNH

November 28, 2021

BioCryst Adds $350 Million in New Financing with Royalty Pharma and OMERS Capital Markets

November 21, 2021

BioCryst Presents New Data Showing Sustained Reduction of HAE Attack Rates and Improved Patient Satisfaction After Patients Switch to ORLADEYO® (berotralstat)

November 4, 2021

BioCryst Reports Third Quarter 2021 Financial Results and Upcoming Key Milestones

November 2, 2021

BioCryst Appoints Jinky Ang Rosselli Chief Data and Insights Officer

October 31, 2021

BioCryst Appoints Dr. Amy McKee to Board of Directors

September 19, 2021

BioCryst Announces Approval of ORLADEYO® (berotralstat) in United Arab Emirates

September 8, 2021

BioCryst Appoints Dr. Steven Galson to Board of Directors

August 25, 2021

BioCryst Announces Acceptance of Regulatory Applications for ORLADEYO® (berotralstat) by Health Canada and Swissmedic

August 24, 2021

BioCryst Commences Public Offering of Common Stock and Pre-Funded Warrants

August 8, 2021

BioCryst Reports Second Quarter 2021 Financial Results and Upcoming Key Milestones

August 4, 2021

BioCryst Appoints Vincent Milano to Board of Directors

July 27, 2021

BioCryst to Report Second Quarter 2021 Financial Results on August 5

July 21, 2021

BioCryst Announces Designs for REDEEM-1 and REDEEM-2 Pivotal Trials with BCX9930 as Oral Monotherapy for Patients with PNH

July 14, 2021

BioCryst Reports 96-week Data from APeX-2 Showing ORLADEYO®(berotralstat) Reduced HAE Attack Rate by 80 Percent from Baseline

July 9, 2021

BioCryst Announces Acceptance and Accelerated Review of the ORLADEYO™ (berotralstat) Marketing Application by the Israeli Ministry of Health

June 15, 2021

BioCryst Launches ORLADEYO™ (berotralstat) in Germany

June 2, 2021

BioCryst Receives UK Approval of ORLADEYO™ (berotralstat), First Oral, Once-daily Therapy to Prevent Attacks in Hereditary Angioedema Patients

May 11, 2021

BioCryst Reports First Quarter 2021 Financial Results and Upcoming Key Milestones

May 5, 2021

BioCryst Receives European Commission Approval of ORLADEYO™ (berotralstat), First Oral, Once-daily Therapy to Prevent Attacks in Hereditary Angioedema Patients

April 29, 2021

BioCryst to Report First Quarter 2021 Financial Results on May 6

April 21, 2021

BioCryst Announces Approval of Japanese NHI Price Listing of ORLADEYO™ (berotralstat) for Prophylactic Treatment of Hereditary Angioedema

April 13, 2021

BioCryst’s Oral Factor D Inhibitor, BCX9930, Advancing to Pivotal Trials in PNH Following Successful Proof of Concept Trial

March 21, 2021

BioCryst Appoints Helen Thackray, M.D., as Chief Research and Development Officer

March 18, 2021

BioCryst to Host Virtual R&D Day on March 22, 2021

March 14, 2021

BioCryst Submits Marketing Authorization Application for UK Approval of ORLADEYO™ (berotralstat), an Oral, Once-daily Therapy to Prevent Attacks in Patients with Hereditary Angioedema

March 1, 2021

BioCryst Receives Positive CHMP Opinion for ORLADEYO™ (berotralstat), an Oral, Once-daily Therapy to Prevent Attacks in Patients with Hereditary Angioedema

February 24, 2021

BioCryst Announces FDA Approval of Supplemental New Drug Application for RAPIVAB® Expanding Patient Population to Include Children Six Months and Older

February 2, 2021

BioCryst Announces Approval of ORLADEYO™ (berotralstat) in Japan for the Prophylactic Treatment of Hereditary Angioedema

January 21, 2021

BioCryst Provides Update on Galidesivir Program

December 21, 2020

BioCryst Announces Positive Phase 1 Results with BCX9250, an Oral ALK-2 Inhibitor for Treatment of Fibrodysplasia Ossificans Progressiva

December 20, 2020

BioCryst Announces U.S. Availability of ORLADEYO™ (berotralstat) for the Treatment of Hereditary Angioedema

December 15, 2020

BioCryst Announces $325 Million of Funding from Royalty Pharma and Athyrium Capital Management

December 6, 2020

BioCryst’s Oral Factor D Inhibitor (BCX9930) Shows High Potency and Specificity for Alternative Pathway of Complement

December 5, 2020

BioCryst Announces FDA Approval of ORLADEYO™ (berotralstat), First Oral, Once-daily Therapy to Prevent Attacks in Hereditary Angioedema Patients

December 2, 2020

BioCryst Reports Third Quarter 2020 Financial Results and Upcoming Key Milestones

November 4, 2020

BioCryst’s Oral Factor D Inhibitor, BCX9930, Shows Clinical Benefit as Monotherapy Through 400 mg bid in Treatment-naïve PNH Patients

September 29, 2020

U.S. Government Exercises Option To Purchase Additional RAPIVAB® from BioCryst for Delivery to Strategic National Stockpile

September 2, 2020

NIAID Awards BioCryst New $44 Million Contract to Advance Development of Galidesivir

August 30, 2020

BioCryst Reports Second Quarter 2020 Financial Results and Upcoming Key Milestones

August 5, 2020

BioCryst to Report Second Quarter 2020 Financial Results on August 6

July 22, 2020

BioCryst Announces Berotralstat Expanded Access Program for Patients with Hereditary Angioedema in United States

June 8, 2020

BioCryst Announces Full Exercise of Underwriters’ Option to Purchase Additional Shares and Completion of Public Offering of Common Stock and Pre-Funded Warrants

May 31, 2020

BioCryst Prices Public Offering of Common Stock and Pre-Funded Warrants

May 26, 2020

BioCryst Reports First Quarter 2020 Financial Results and Upcoming Key Milestones

May 5, 2020

← Newer news releases · Older news releases →

Calls

The 5 newest of 25 calls. Every call is listed under its year.

Decks

The 5 newest of 36 decks. Every deck is listed under its year.